JP2010516677A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010516677A5 JP2010516677A5 JP2009546419A JP2009546419A JP2010516677A5 JP 2010516677 A5 JP2010516677 A5 JP 2010516677A5 JP 2009546419 A JP2009546419 A JP 2009546419A JP 2009546419 A JP2009546419 A JP 2009546419A JP 2010516677 A5 JP2010516677 A5 JP 2010516677A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- diarrhea
- antioxidants
- enteritis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 206010012735 Diarrhoea Diseases 0.000 claims 4
- 208000004232 Enteritis Diseases 0.000 claims 4
- 239000003963 antioxidant agent Substances 0.000 claims 4
- 235000006708 antioxidants Nutrition 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 4
- 239000007909 solid dosage form Substances 0.000 claims 4
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims 3
- 241000193163 Clostridioides difficile Species 0.000 claims 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 3
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims 3
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims 2
- 229920002472 Starch Polymers 0.000 claims 2
- 230000000845 anti-microbial effect Effects 0.000 claims 2
- 206010009887 colitis Diseases 0.000 claims 2
- VFPFQHQNJCMNBZ-UHFFFAOYSA-N ethyl gallate Chemical compound CCOC(=O)C1=CC(O)=C(O)C(O)=C1 VFPFQHQNJCMNBZ-UHFFFAOYSA-N 0.000 claims 2
- 229920001903 high density polyethylene Polymers 0.000 claims 2
- 239000004700 high-density polyethylene Substances 0.000 claims 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims 2
- 229940079832 sodium starch glycolate Drugs 0.000 claims 2
- 229920003109 sodium starch glycolate Polymers 0.000 claims 2
- 239000008109 sodium starch glycolate Substances 0.000 claims 2
- 229940032147 starch Drugs 0.000 claims 2
- 235000019698 starch Nutrition 0.000 claims 2
- 239000008107 starch Substances 0.000 claims 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 claims 1
- 241000193403 Clostridium Species 0.000 claims 1
- 206010009657 Clostridium difficile colitis Diseases 0.000 claims 1
- 241000193468 Clostridium perfringens Species 0.000 claims 1
- 241001478240 Coccus Species 0.000 claims 1
- 206010012742 Diarrhoea infectious Diseases 0.000 claims 1
- RPWFJAMTCNSJKK-UHFFFAOYSA-N Dodecyl gallate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC(O)=C(O)C(O)=C1 RPWFJAMTCNSJKK-UHFFFAOYSA-N 0.000 claims 1
- 241000194033 Enterococcus Species 0.000 claims 1
- 239000004262 Ethyl gallate Substances 0.000 claims 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 claims 1
- 206010037128 Pseudomembranous colitis Diseases 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- 229940087168 alpha tocopherol Drugs 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 claims 1
- 235000010386 dodecyl gallate Nutrition 0.000 claims 1
- 239000000555 dodecyl gallate Substances 0.000 claims 1
- 229940080643 dodecyl gallate Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000001848 dysentery Diseases 0.000 claims 1
- 235000019277 ethyl gallate Nutrition 0.000 claims 1
- 235000011087 fumaric acid Nutrition 0.000 claims 1
- 239000001530 fumaric acid Substances 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 229960004592 isopropanol Drugs 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 229940057948 magnesium stearate Drugs 0.000 claims 1
- 235000011090 malic acid Nutrition 0.000 claims 1
- 239000001630 malic acid Substances 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 235000010387 octyl gallate Nutrition 0.000 claims 1
- 239000000574 octyl gallate Substances 0.000 claims 1
- NRPKURNSADTHLJ-UHFFFAOYSA-N octyl gallate Chemical compound CCCCCCCCOC(=O)C1=CC(O)=C(O)C(O)=C1 NRPKURNSADTHLJ-UHFFFAOYSA-N 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 235000010388 propyl gallate Nutrition 0.000 claims 1
- 239000000473 propyl gallate Substances 0.000 claims 1
- 229940075579 propyl gallate Drugs 0.000 claims 1
- 235000010378 sodium ascorbate Nutrition 0.000 claims 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 claims 1
- 229960005055 sodium ascorbate Drugs 0.000 claims 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims 1
- 229940001584 sodium metabisulfite Drugs 0.000 claims 1
- 235000010262 sodium metabisulphite Nutrition 0.000 claims 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 claims 1
- 238000011105 stabilization Methods 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 229960004274 stearic acid Drugs 0.000 claims 1
- 229960000984 tocofersolan Drugs 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- 235000004835 α-tocopherol Nutrition 0.000 claims 1
- 239000002076 α-tocopherol Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88113707P | 2007-01-19 | 2007-01-19 | |
| US60/881,137 | 2007-01-19 | ||
| PCT/US2008/000591 WO2008091518A1 (en) | 2007-01-19 | 2008-01-17 | Compositions of stable tiacumicins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014129106A Division JP5995331B2 (ja) | 2007-01-19 | 2014-06-24 | 安定なチアクミシン組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010516677A JP2010516677A (ja) | 2010-05-20 |
| JP2010516677A5 true JP2010516677A5 (enExample) | 2011-03-03 |
| JP5635266B2 JP5635266B2 (ja) | 2014-12-03 |
Family
ID=39641896
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009546419A Active JP5635266B2 (ja) | 2007-01-19 | 2008-01-17 | 安定なチアクミシン組成物 |
| JP2014129106A Active JP5995331B2 (ja) | 2007-01-19 | 2014-06-24 | 安定なチアクミシン組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014129106A Active JP5995331B2 (ja) | 2007-01-19 | 2014-06-24 | 安定なチアクミシン組成物 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20080176927A1 (enExample) |
| EP (1) | EP2121716B1 (enExample) |
| JP (2) | JP5635266B2 (enExample) |
| KR (1) | KR101491729B1 (enExample) |
| CN (2) | CN105169396A (enExample) |
| BR (1) | BRPI0806713A8 (enExample) |
| CA (1) | CA2676003C (enExample) |
| CY (1) | CY1117237T1 (enExample) |
| DK (1) | DK2121716T3 (enExample) |
| ES (1) | ES2560669T3 (enExample) |
| HR (1) | HRP20151438T1 (enExample) |
| HU (1) | HUE028671T2 (enExample) |
| IL (1) | IL199941A (enExample) |
| MX (1) | MX2009007784A (enExample) |
| NZ (1) | NZ578493A (enExample) |
| PL (1) | PL2121716T3 (enExample) |
| PT (1) | PT2121716E (enExample) |
| RU (1) | RU2484829C2 (enExample) |
| SI (1) | SI2121716T1 (enExample) |
| TW (1) | TWI474820B (enExample) |
| WO (1) | WO2008091518A1 (enExample) |
| ZA (1) | ZA200905134B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7906489B2 (en) | 2004-05-14 | 2011-03-15 | Optimer Pharmaceuticals, Inc. | 18-membered macrocycles and analogs thereof |
| US7378508B2 (en) | 2007-01-22 | 2008-05-27 | Optimer Pharmaceuticals, Inc. | Polymorphic crystalline forms of tiacumicin B |
| TWI523654B (zh) | 2007-11-27 | 2016-03-01 | 默沙東藥廠 | 抗生素巨環化合物以及其製造及使用之方法 |
| CA2799531A1 (en) * | 2010-05-18 | 2011-11-24 | Optimer Pharmaceuticals, Inc. | Treating recurring clostridium difficile infection using fidaxomicin |
| MX2012013374A (es) * | 2010-05-18 | 2013-05-06 | Optimer Pharmaceuticals Inc | Tratamiento de infecciones de clostridium difficile en pacientes bajo terapia con antibioticos. |
| ES2654945T3 (es) * | 2010-06-02 | 2018-02-15 | Diffusion Pharmaceuticals Llc | Formulaciones orales de carotenoides trans bipolares |
| US20140024609A1 (en) * | 2011-02-04 | 2014-01-23 | Optimer Pharmaceuticals ,Inc. | Treatment of Bacterial Infections |
| ITMI20120560A1 (it) | 2012-04-05 | 2013-10-06 | Olon Spa | Procedimento per la purificazione della tiacumicina b |
| JO3464B1 (ar) * | 2013-01-15 | 2020-07-05 | Astellas Pharma Europe Ltd | التركيبات الخاصة بمركبات التياكوميسين |
| US20150141356A1 (en) * | 2013-11-15 | 2015-05-21 | Optimer Pharmaceuticals, Inc. | Treatment of Clostridium Difficile Infection in High Risk Patients |
| WO2015127955A1 (en) | 2014-02-25 | 2015-09-03 | Olon S.P.A. | A new polymorph of tiacumicin b and process for preparation thereof |
| DK3139932T3 (en) * | 2014-05-09 | 2018-11-12 | Astellas Pharma Europe Ltd | The treatment regimen for thiacumicin compound |
| CN110037992B (zh) * | 2019-05-28 | 2021-05-28 | 杭州华东医药集团新药研究院有限公司 | 一种稳定的非达霉素组合物 |
| CN112353774B (zh) * | 2020-11-17 | 2022-08-23 | 浙江汇能生物股份有限公司 | 一种那西肽风味咀嚼片及其制备方法及其在犬魏氏梭菌病上的用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05192094A (ja) * | 1991-09-03 | 1993-08-03 | Takeda Chem Ind Ltd | 造粒組成物 |
| US5583115A (en) * | 1995-05-09 | 1996-12-10 | Abbott Laboratories | Dialkyltiacumicin compounds |
| WO2002032427A1 (en) * | 2000-10-20 | 2002-04-25 | Galephar M/F | Stable oral formulation containing benzimidazole derivative |
| US20030099699A1 (en) * | 2001-11-13 | 2003-05-29 | Hanshew Dwight D. | Storage stable thyroxine active drug formulations and methods for their production |
| WO2004014295A2 (en) * | 2002-07-29 | 2004-02-19 | Optimer Pharmaceuticals, Inc. | Tiacumicin production |
| WO2006085838A1 (en) | 2005-01-31 | 2006-08-17 | Optimer Pharmaceuticals, Inc. | 18-membered macrocycles and analogs thereof |
| US9211259B2 (en) * | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
| CA2510465A1 (en) * | 2002-12-18 | 2004-07-08 | Pain Therapeutics | Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats |
| US7906489B2 (en) * | 2004-05-14 | 2011-03-15 | Optimer Pharmaceuticals, Inc. | 18-membered macrocycles and analogs thereof |
-
2008
- 2008-01-14 US US12/008,751 patent/US20080176927A1/en not_active Abandoned
- 2008-01-17 BR BRPI0806713A patent/BRPI0806713A8/pt not_active Application Discontinuation
- 2008-01-17 EP EP08724557.7A patent/EP2121716B1/en active Active
- 2008-01-17 NZ NZ578493A patent/NZ578493A/en unknown
- 2008-01-17 KR KR1020097017319A patent/KR101491729B1/ko not_active Expired - Fee Related
- 2008-01-17 WO PCT/US2008/000591 patent/WO2008091518A1/en not_active Ceased
- 2008-01-17 RU RU2009128612/15A patent/RU2484829C2/ru active
- 2008-01-17 JP JP2009546419A patent/JP5635266B2/ja active Active
- 2008-01-17 SI SI200831576T patent/SI2121716T1/sl unknown
- 2008-01-17 ES ES08724557.7T patent/ES2560669T3/es active Active
- 2008-01-17 HU HUE08724557A patent/HUE028671T2/en unknown
- 2008-01-17 PT PT87245577T patent/PT2121716E/pt unknown
- 2008-01-17 DK DK08724557.7T patent/DK2121716T3/en active
- 2008-01-17 PL PL08724557T patent/PL2121716T3/pl unknown
- 2008-01-17 CA CA2676003A patent/CA2676003C/en active Active
- 2008-01-17 CN CN201510502516.0A patent/CN105169396A/zh active Pending
- 2008-01-17 HR HRP20151438TT patent/HRP20151438T1/hr unknown
- 2008-01-17 MX MX2009007784A patent/MX2009007784A/es active IP Right Grant
- 2008-01-17 CN CN2008800078761A patent/CN102015747A/zh active Pending
- 2008-03-10 TW TW097108321A patent/TWI474820B/zh active
-
2009
- 2009-07-19 IL IL199941A patent/IL199941A/en active IP Right Grant
- 2009-07-22 ZA ZA2009/05134A patent/ZA200905134B/en unknown
-
2012
- 2012-03-09 US US13/416,768 patent/US20130065844A1/en not_active Abandoned
-
2014
- 2014-06-24 JP JP2014129106A patent/JP5995331B2/ja active Active
-
2016
- 2016-03-01 CY CY20161100177T patent/CY1117237T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010516677A5 (enExample) | ||
| CA2676003A1 (en) | Compositions of stable tiacumicins | |
| JP2014205701A5 (enExample) | ||
| FI2508188T3 (fi) | Dapagliflotsiinipropyleeniglykolihydraattia sisältäviä farmaseuttisia formulaatioita | |
| US20210205324A1 (en) | Methods of treatment and pharmaceutical compositions using an sglt-2 inhibitor and a neuroleptic agent | |
| JP2011068653A5 (enExample) | ||
| EP2273985B1 (en) | Capsule for the prevention of cardiovascular diseases | |
| ES2916649T1 (es) | Composiciones y usos para el tratamiento de la esclerosis múltiple | |
| IL314360B2 (en) | Method for the synthesis of thyroid hormone analogs and their polymorphs | |
| JP2016503030A5 (enExample) | ||
| JP5854571B2 (ja) | におい抑制方法 | |
| WO2012162439A2 (en) | Compositions comprising fusidic acid and packages therefor | |
| JP2024014994A (ja) | 医薬組成物（３） | |
| US20190254977A1 (en) | Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine | |
| KR20140044628A (ko) | 신규한 폴리에틸렌글리콜과 비타민 씨를 함유하는 안정성이 개선된 장관 하제 조성물 | |
| CA2505130C (en) | Pharmaceutical compositions | |
| CA2627544A1 (en) | Formulations of quinolinones for the treatment of cancer | |
| CA2797458A1 (en) | Tablet formulation of ezatiostat | |
| JP2013528213A5 (enExample) | ||
| WO2010026469A1 (es) | Composición farmacéutica para el uso en el tratamiento de infecciones de transmisión sexual | |
| RU2012136190A (ru) | Фармацевтический состав для профилактики или лечения артрозоартрита, содержащий ребамипид в качестве активного ингредиента | |
| WO2019101151A1 (zh) | 一种海泽麦布和HMG-CoA还原酶抑制剂的药物组合物 | |
| RU2007135367A (ru) | Твердая фармацевтическая композиция, содержащая телитромицин | |
| ES2280150T1 (es) | Combinacion de fluconazol-tinidazol para el tratamiento de infecciones vaginales, composicion de la misma y preparacion y uso de la misma. | |
| AU2013223749A1 (en) | Stable dosage forms of imatinib mesylate |